Furthermore, another study investigated the correlation between the expression of P-gp, GST and metallothioneins (MTs) and the response to various chemotherapy regimens in triple--negative (ER-, PR- and HER2-negative) breast cancer patients (13). This evidence concerns the gene ERBB2 and breast cancer.